Biotech heavyweight Biogen (NASDAQ:BIIB) saw its shares sink by as much as 32% in pre-market trading Monday. The biotech's stock is under serious pressure today following a negative advisory committee vote for its experimental Alzheimer's disease drug aducanumab last Friday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,